Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 10 records in total 11
    records per page




    Cardiac Arrhythmias MESHD Arrhythmias HP in Patients with COVID-19: A Systematic review and Meta-analysis

    Authors: Omar Hamam; Ahmed Goda; Moustafa Eldalal; Amr Ussama; Omar Elmandouh; Mostafa Fahmy; Karim Elyamany; Waleed Ikram; Ahmed Mahdy; Renu Bhandari; Hosam Asal; Alexander Egbe; Ana Catharina Nastri; Maura Salaroli de Oliveira; José Mauro Vieira Junior; Esper Georges Kallas; Anna Sara Levin; Ester Cerdeira Sabino; Silvia Figueiredo Costa

    doi:10.1101/2020.10.09.20209379 Date: 2020-10-13 Source: medRxiv

    Background: Cardiac arrhythmia MESHD arrhythmia HP cannot be overlooked in patients with coronavirus disease MESHD 2019 (COVID-19) as it carries a great influence on the outcomes. Hence, this study aimed to build concrete evidence regarding the incidence of cardiac arrhythmia MESHD arrhythmia HP in patients with COVID-19. Methods: We performed a systematic search for trusted databases/search engines including PubMed, Scopus, Cochrane library and web of science. After screening, the relevant data were extracted and the incidences from the different included studies were pooled for meta-analysis. Results: Nine studies were finally included in our study consisting of 1445 patients. The results of meta-analysis showed that the incidence of arrhythmia HP arrhythmia MESHD in patients with COVID-19 was 19.7% with 95% confidence interval (CI) ranging from 11.7 to 27.6%. There was also a significant heterogeneity (I2 = 94.67%). Conclusion: Cardiac arrhythmias MESHD arrhythmias HP were highly frequent in patients with COVID-19 and observed in 19.7% of them. Appropriate monitoring by electrocardiogram with accurate and early identification of arrhythmias HP arrhythmias MESHD is important for better management and outcomes.

    Safety measures for COVID-19 do not compromise the outcomes of patients undergoing primary percutaneous coronary intervention: A single center study

    Authors: Xiaonan Guan; Jianjun Zhang; Yanbing Li; Ning Ma

    doi:10.21203/rs.3.rs-88850/v1 Date: 2020-10-06 Source: ResearchSquare

    Coronavirus disease MESHD 2019 (COVID-19) is a global pandemic impacting nearly 170 countries/regions and millions of patients worldwide. Patients with acute myocardial infarction MESHD myocardial infarction HP ( AMI MESHD) still need to be treated at percutaneous coronary intervention (PCI) centers with relevant safety measures. This study was conducted to assess the therapeutic outcomes of PCI performed under the safety measures and normal conditions. AMI MESHD patients undergoing PCI between January 24 to April 30, 2020 were performed under safety measures for COVID-19. Patients received pulmonary computed tomography (CT) and underwent PCI in negative pressure ICU. Cardiac catheterization laboratory (CCL) staff and physicians worked with level Ⅲ personal protection. Demographic and clinical data, such as door-to-balloon (DTB) time, operation time, complications for patients in this period (NCP group) and the same period in 2019 (2019 group) were retrieved and analyzed. NCP and 2019 groups had 37 and 96 patients, respectively. There was no significant difference in age TRANS, gender TRANS, BMI and comorbidity between the two groups. DTB time and operation time were similar between the two groups (60.0 ± 12.39 vs 58.83 ± 12.85 min, p = 0.636; 61.46 ± 9.91 vs 62.55 ± 10.72 min, p = 0.592). Hospital stay time in NCP group was significantly shorter (6.78 ± 2.14 vs 8.85 ± 2.64 days, p < 0.001). The incidences of malignant arrhythmia MESHD arrhythmia HP and Takotsubo Syndrome MESHD in NCP group were higher than 2019 group significantly (16.22% vs 5.21%, p = 0.039; 10.81% vs 1.04% p = 0.008). During hospitalization and 3-month follow-up, the incidence of major adverse cardiovascular events and mortality in the two groups were statistically similar (35.13% vs 14.58%, p = 0.094; 16.22% vs 8.33%, p =0.184). Our analysis showed that safety measures undertaken in this hospital, including screening of COVID-19 infection MESHD and use of personal protection equipment for conducting PCI did not compromise the surgical outcome as compared with PCI under normal condition, although there were slight increases in incidence of malignant arrhythmia MESHD arrhythmia HP and Takotsubo Syndrome MESHD.

    Findings on the relationship between cardiovascular disease MESHD and coronavirus disease MESHD 2019: a systematic review

    Authors: Yuri Henrique da Silva1; José Gildo de Moura Monteiro Júnior; Rosângela Ferreira Frade de Araújo

    doi:10.21203/rs.3.rs-84991/v1 Date: 2020-09-28 Source: ResearchSquare

    Coronavirus disease 2019 (COVID-19) presents as the main cause of death MESHD, respiratory and heart failures MESHD, especially in the elderly TRANS, immunosuppressed, and those with cardiovascular comorbidities. Therefore, a better understanding of these findings is needed. A systematic review was carried out looking for articles published between December 2019 and May 2020 on the MEDLINE / PubMed search platform using the following descriptors: (((((((((" cardiovascular disease MESHD") OR ("acute myocardial infarction HP myocardial infarction MESHD")) OR (" coronary artery disease MESHD")) OR ("acute coronary syndrome MESHD")) OR (" atherosclerosis HP atherosclerosis MESHD")) OR (" cardiac insufficiency MESHD")) OR (" pericarditis HP pericarditis MESHD")) OR (" myocarditis HP myocarditis MESHD")) AND ("COVID-19")) OR ("SARS-CoV-2")and considering inclusion and exclusion criteria.40% of patients infected with SARS-CoV-2 had hypertension HP hypertension MESHD or other cardiovascular comorbidities, while 27% presented cardiovascular complications, mainly acute cardiac injury MESHD, arrhythmia HP arrhythmia MESHD and heart failure MESHD. The hypotheses of involvement of an intense inflammatory response, decreased HP immunity and greater expression of ACE2 in the heart, associated with more severe heart conditions, were discussed in this study. The increase in cardiac and inflammatory markers was associated with worse clinical outcomes and risk of death MESHD, confirming the need to evaluate them since admission to the hospital. The 10 articles analyzed presented as a limitation the small number of patients inserted, to the detriment of the pandemic state. We warned about the need for better clinical management of patients with cardiovascular comorbidities MESHD, and the importance of including this group among the first to be immunized, aiming at reducing the number of fatal cases due to infection MESHD. Studies with greater coverage are needed for a better comprehension of the topics discussed here.

    Observations on echocardiographic findings in patients with COVID-19

    Authors: Ahsan A Khan; Sunil James; Mengshi Yuan; Latoya Woolery; Nina Huppertz; Mushidur Rahman; Chetan Varma; Stavros Apostolakis; Vinoda Sharma

    doi:10.21203/rs.3.rs-58076/v1 Date: 2020-08-12 Source: ResearchSquare

    Background The novel coronavirus (SARS-CoV-2) has created global havoc by causing Coronavirus Disease MESHD 2019 (COVID-19). Cardiovascular involvement MESHD in COVID-19 varies from troponin rise or arrhythmia HP arrhythmia MESHD/ myocarditis HP myocarditis MESHD to fulminant cardiogenic shock HP cardiogenic shock MESHD. There is limited data on echocardiographic findings in such patients. We aimed to assess abnormal echocardiographic findings and contributory factors in patients with COVID-19.Methods We performed retrospective analysis of COVID-19 positive patients who underwent a transthoracic echocardiogram (TTE) at Sandwell and West Birmingham (SWBH) NHS Trust between March 2020 and May 2020. Patients were compared based on TTE changes and divided into two groups (abnormal TTE and normal TTE).Results 66 out of 463 patients with COVID-19 had a TTE. 46 patients (69.7%) had abnormal findings on their TTE. Tricuspid regurgitation HP Tricuspid regurgitation MESHD was the most common abnormality observed (26 (56.5%) patients), followed by aortic regurgitation HP aortic regurgitation MESHD (13 (28.3%) patients) and mitral regurgitation HP mitral regurgitation MESHD (12 (26.1%) patients). Haemoglobin and LDH were predictors of abnormal TTE (Hb OR: 0.97, p = 0.049, LDH, OR: 1.00, p = 0.03). Significantly more patients in the abnormal TTE group died during their inpatient stay compared to normal TTE (p = 0.01). Having an abnormal TTE was an independent predictor of death on regression analysis (OR: 0.229, p = 0.034).Conclusions This is the first detailed observational study looking at echocardiographic changes in admitted COVID-19 patients irrespective of disease severity. The most common abnormality was valve regurgitation MESHD. Patients with abnormal TTE were more likely to die in hospital.

    The Spectrum of Cardiovascular Complications MESHD in COVID-19- A Comprehensive Literature Review

    Authors: Raja Shakeel Mushtaque; Rabia Mushtaque; Shahbano Baloch; Aadil Raza; Haseeb Bhatti; Zohaib Khan

    id:10.20944/preprints202008.0257.v1 Date: 2020-08-11 Source: Preprints.org

    A newly identified novel coronavirus named as severe acute respiratory syndrome MESHD-related coronavirus2 (SARS‐CoV 2) has given rise to the global pandemic. SARS-CoV2 which causes coronavirus disease MESHD 2019 (COVID-19), is a positive-stranded RNA virus with nucleocapsid. It binds to host angiotensin-converting enzyme2 (ACE2) receptor through surface glycoprotein (S protein). These ACE 2 receptors are attached to the cell membranes of many organs. Thus, COVID-19 does not only result in acute respiratory distress syndrome MESHD respiratory distress HP syndrome but also affects multiple organ systems, requiring a multidisciplinary approach to manage this disease. COVID-19 can damage the myocardial cells and result in fulminant myocarditis HP myocarditis MESHD, acute cardiac injury MESHD, cardiomyopathy HP cardiomyopathy MESHD, heart failure MESHD, cardiogenic shock HP cardiogenic shock MESHD, or arrhythmia HP arrhythmia MESHD. COVID-19 seeds harmful immune response through cytokine storm leading to indirect organ damage. In this literature review, the available data is comprehended regarding cardiovascular complications in COVID-19, and the correlation of biomarkers with the disease activity is discussed. This literature review also highlights the important treatment options and outcomes of the individual study.

    Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.

    Authors: Peter Horby; Marion Mafham; Louise Linsell; Jennifer L Bell; Natalie Staplin; Jonathan R Emberson; Martin Wiselka; Andrew Ustianowski; Einas Elmahi; Benjamin Prudon; Anthony Whitehouse; Timothy Felton; John Williams; Jakki Faccenda; Jonathan Underwood; J Kenneth Baillie; Lucy Chappell; Saul N Faust; Thomas Jaki; Katie Jeffery; Wei Shen Lim; Alan Montgomery; Kathryn Rowan; Joel Tarning; James A Watson; Nicholas J White; Edmund Juszczak; Richard Haynes; Martin J Landray

    doi:10.1101/2020.07.15.20151852 Date: 2020-07-15 Source: medRxiv

    Background: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease MESHD 2019 (COVID-19) on the basis of in vitro activity, uncontrolled data, and small randomized studies. Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of hydroxychloroquine vs. usual care alone. The primary outcome was 28-day mortality. Results: 1561 patients randomly allocated to receive hydroxychloroquine were compared with 3155 patients concurrently allocated to usual care. Overall, 418 (26.8%) patients allocated hydroxychloroquine and 788 (25.0%) patients allocated usual care died within 28 days (rate ratio 1.09; 95% confidence interval [CI] 0.96 to 1.23; P=0.18). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to hydroxychloroquine were less likely to be discharged from hospital alive within 28 days (60.3% vs. 62.8%; rate ratio 0.92; 95% CI 0.85-0.99) and those not on invasive mechanical ventilation at baseline were more likely to reach the composite endpoint of invasive mechanical ventilation or death MESHD (29.8% vs. 26.5%; risk ratio 1.12; 95% CI 1.01-1.25). There was no excess of new major cardiac arrhythmia MESHD arrhythmia HP. Conclusions: In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death MESHD.

    Cardiovascular Implications of Coronavirus Disease MESHD 2019 (COVID-19): A Systematic Review

    Authors: Ravi Ranjan Pradhan; Ajay Kumar Yadav; Shobha Mandal

    doi:10.21203/rs.3.rs-39929/v1 Date: 2020-07-02 Source: ResearchSquare

    Background: World Health Organization has declared Coronavirus disease MESHD (COVID-19) as a Public Health Emergency of International Concern. It has killed thousands and millions are infected worldwide. Though COVID-19 is supposed to be primarily a disease of respiratory system, it also has widespread implications on other systems as well. The aim of this systematic review is to summarize the cardiovascular implications of COVID-19. Methods: PubMed, PubMed Central, EMBASE, and Google Scholar were searched for peer-reviewed articles which aimed to delineate the cardiovascular implications of COVID-19.Results: A total of six articles (five original articles and one case report) were included. We found diverse cardiovascular implications of COVID-19 ranging from acute cardiac injury to death MESHD. New onset abnormalities in electrocardiogram or echocardiogragram, elevated plasma SERO levels of cardiac troponin, NT-proBNP, and D-dimer have role in early identification of acute cardiac injury MESHD in such patients. Additionally, cardiac troponin and NT-proBNP can be used to evaluate prognosis and possible need for intensive care in these patients.Conclusion: Acute cardiac injury MESHD is common in patients with COVID-19. Aggressive supportive management based on prognostic indicators along with management of heart failure MESHD, arrhythmias HP arrhythmias MESHD, acute coronary syndrome MESHD and thrombosis MESHD can improve clinical outcomes in such patients.

    Cardiac Arrhythmias MESHD Arrhythmias HP and COVID-19 – a Meta-analysis of Recent Reports

    Authors: Husam M. I. Salah; Jawahar L. Mehta

    doi:10.21203/rs.3.rs-37700/v1 Date: 2020-06-23 Source: ResearchSquare

    Introduction: The 2019 novel coronavirus disease MESHD (COVID-19) is a current pandemic. Cardiovascular manifestations of COVID-19 have been described in many studies; however, no studies have examined the prevalence SERO and characterizations of cardiac arrhythmias MESHD arrhythmias HP among patients with COVID-19 infection MESHD. The aim of this meta-analysis was to examine the prevalence SERO of cardiac arrhythmias MESHD arrhythmias HP among patients with COVID-19 infection MESHD.Method: PubMed, Google Scholar, and ResearchGate databases were searched for relevant articles from inception until June 14, 2020. Inclusion criteria were: 1) Cohort studies or case series studies; 2) Study population included individuals with confirmed COVID-19 infection MESHD; 3) Arrhythmic events were reported in the study. All other studies were excluded. MedCalc software was used to analyze the pooled data. The random-effect model was utilized to obtain the prevalence SERO of arrhythmia HP arrhythmia MESHD among the included patients and its 95% confidence interval. Cohran's Q and I2 index were used for heterogeneity measurements. The main planned outcome was the prevalence SERO of arrhythmia HP arrhythmia MESHD among patients with COVID-19 infection MESHD.Results: Thirteen studies with a total of 2861 patients met our inclusion criteria. The prevalence SERO of arrhythmia HP arrhythmia MESHD among patients with COVID-19 infection MESHD was 8.1% (95% CI [6.10, 10.37]). 82.8% of the patients who had arrhythmia HP arrhythmia MESHD has severe illness (95% CI [70.916, 92.124]).Conclusion: The prevalence SERO of arrhythmias HP arrhythmias MESHD among patients with COVID-19 infection MESHD is 8.1%, which is much higher than in the general population (2.35%). 

    Human iPSC-Derived Cardiomyocytes are Susceptible to SARS-CoV-2 Infection MESHD

    Authors: Arun Sharma; Gustavo Garcia Jr.; Vaithilingaraja Arumugaswami; Clive N Svendsen

    doi:10.1101/2020.04.21.051912 Date: 2020-04-21 Source: bioRxiv

    Coronavirus disease 2019 (COVID-19) is a viral pandemic caused by the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). COVID-19 is predominantly defined by respiratory symptoms, but cardiac complications including arrhythmias HP arrhythmias MESHD, heart failure MESHD, and viral myocarditis HP myocarditis MESHD are also prevalent. Although the systemic ischemic MESHD and inflammatory responses caused by COVID-19 can detrimentally affect cardiac function, the direct impact of SARS-CoV-2 infection MESHD on human cardiomyocytes is not well-understood. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as a model system to examine the mechanisms of cardiomyocyte-specific infection by SARS-CoV-2. Microscopy and immunofluorescence demonstrated that SARS-CoV-2 can enter and replicate within hiPSC-CMs, localizing at perinuclear locations within the cytoplasm. Viral cytopathic effect induced hiPSC-CM apoptosis MESHD and cessation of beating after 72 hours of infection MESHD. These studies show that SARS-CoV-2 can infect hiPSC-CMs MESHD in vitro, establishing a model for elucidating the mechanisms of infection MESHD and potentially a cardiac-specific antiviral drug screening platform.

    Cardiovascular Diseases MESHD and COVID-19 Mortality and Intensive Care Unit Admission: A Systematic Review and Meta-analysis

    Authors: Amirhossein Hessami; Amir Shamshirian; Keyvan Heydari; Fatemeh Pourali; Reza Alizadeh-Navaei; Mahmood Moosazadeh; Saeed Abrotan; Layla Shojaei; Sogol Sedighi; Danial Shamshirian; Nima Rezaei

    doi:10.1101/2020.04.12.20062869 Date: 2020-04-16 Source: medRxiv

    Background: High rate of cardiovascular disease MESHD ( CVD MESHD) have been reported among patients with novel coronavirus disease MESHD (COVID-19). Meanwhile there were controversies among different studies about CVD MESHD burden in COVID-19 patients. Hence, we aimed to study CVD MESHD burden among COVID-19 patients, using a systematic review and meta-analysis. Methods: We have systematically searched databases including PubMed, Embase, Cochrane Library, Scopus, Web of Science as well as medRxiv pre-print database. Hand searched was also conducted in journal websites and Google Scholar. Meta-analyses were carried out for Odds Ratio (OR) of mortality and Intensive Care Unit (ICU) admission for different CVDs. We have also performed a descriptive meta-analysis on different CVDs. Results: Fifty-six studies entered into meta-analysis for ICU admission and mortality outcome and 198 papers for descriptive outcomes, including 159,698 COVID-19 patients. Results of meta-analysis indicated that acute cardiac injury MESHD, (OR: 13.29, 95% CI 7.35-24.03), hypertension HP hypertension MESHD (OR: 2.60, 95% CI 2.11-3.19), heart Failure MESHD (OR: 6.72, 95% CI 3.34-13.52), arrhythmia HP arrhythmia MESHD (OR: 2.75, 95% CI 1.43-5.25), coronary artery disease MESHD (OR: 3.78, 95% CI 2.42-5.90), and cardiovascular disease MESHD (OR: 2.61, 95% CI 1.89-3.62) were significantly associated with mortality. Arrhythmia HP Arrhythmia MESHD (OR: 7.03, 95% CI 2.79-17.69), acute cardiac injury MESHD (OR: 15.58, 95% CI 5.15-47.12), coronary heart disease MESHD (OR: 2.61, 95% CI 1.09-6.26), cardiovascular disease MESHD (OR: 3.11, 95% CI 1.59-6.09), and hypertension HP hypertension MESHD (OR: 1.95, 95% CI 1.41-2.68) were also significantly associated with ICU admission in COVID-19 patients. Conclusion: Findings of this study revealed a high burden of CVDs among COVID-19 patients, which was significantly associated with mortality and ICU admission. Proper management of CVD MESHD patients with COVID-19 and monitoring COVID-19 patients for acute cardiac conditions is highly recommended to prevent mortality and critical situations.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.